ALOXI OFFERS IMPROVED CINV CONTROL VERSUS DOLASETRON1
- Pivotal, double-blind, controlled phase III clinical trial involved patients receiving moderately emetogenic chemotherapy.
- Patients were balanced across treatment groups.
EFFECTIVE EMESIS PREVENTION1
97.5% Confidence Interval (CI) and two-sided Fisher's exact test (significance level=0.025) indicate a difference between ALOXI and dolasetron.
†Intent-to-treat cohort.
EARLY SEPARATION IN CONTROL RATES1
- ALOXI provided a significantly longer time to treatment failure than dolasetron (p<0.017).1
- Separation in control rates appeared as early as day 1.1
- Efficacy in the acute phase is a positive predicator of efficacy in the delayed phase.2
*Statistically significant vs dolasetron (p<0.017).
†Intent-to-treat cohort
Click here to view the results of ALOXI vs. Ondansetron and Dolasetron: Pooled Data.
References
- Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
- Mantovani G, Macció A, Curreli L, et al. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus IM dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. Oncol Rep. 1998;5:273-280.